Correspondence 0001493152-25-009853 from GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc.
Date: March 11, 2025 · CIK: 0000109657 · Accession: 0001493152-25-009853
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285618
Letter
GT Biopharma, Inc.
March 11, 2025
VIA EDGAR
Division of Corporation Finance
United States Securities and Exchange Commission
F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford, Office of Life Sciences
Re: GT Biopharma, Inc. Acceleration Request for Registration Statement on Form S-3
File No. 333-285618
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-285618) be declared effective at 4:00 p.m. Eastern Time on March 13, 2025, or as soon as practicable thereafter.
Once the Registration Statement has been declared effective, please confirm that event with our counsel, Louis Wharton of Stubbs Alderton & Markiles, LLP, by email at lwharton@stubbsalderton.com or by telephone at (818)-444-4509.
Very truly yours,
GT Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm GT Biopharma, Inc. March 11, 2025 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford, Office of Life Sciences Re: GT Biopharma, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-285618 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-285618) be declared effective at 4:00 p.m. Eastern Time on March 13, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Louis Wharton of Stubbs Alderton & Markiles, LLP, by email at lwharton@stubbsalderton.com or by telephone at (818)-444-4509. Very truly yours, GT Biopharma, Inc. By: /s/ Alan Urban Alan Urban Chief Financial Officer